Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications - PubMed (original) (raw)
Review
Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications
Gaetano Leto et al. Clin Exp Metastasis. 2004.
Free article
Abstract
Cathepsin D is a lysosomal acid proteinase which is involved in the malignant progression of breast cancer and other gynecological tumors. Clinical investigations have shown that in breast cancer patients cathepsin D overexpression was significantly correlated with a shorter free-time disease and overall survival, whereas in patients with ovarian or endometrial cancer this phenomenon was associated with tumor aggressiveness and a degree of chemoresistance to various antitumor drugs such as anthracyclines, cis-platinum and vinca alkaloids. Therefore, a lot of research has been undertaken to evaluate the role and the prognostic value of cathepsin D also in other solid neoplasms. However, conflicting results have been generated from these studies. The discrepancies in these results may, in part, be explained with the different methodological approaches used in order to determine the levels of expression of the enzyme in tumor tissues and body fluids. Further investigations using well-standardized techniques may better define the clinical significance of cathepsin D expression in solid tumors. Nevertheless, evidence emerging from these studied indicates that this proteinase seems to facilitate early phases of tumor progression such as cell proliferation and local dissemination. These findings support the concept that cathepsin D may be a useful marker for identifying patients with highly malignant tumor phenotypes who may need more aggressive clinical treatment; this enzyme may also be considered as a potential target for a novel therapeutic approach in the treatment of solid neoplasms.
Similar articles
- The dilemma: does tissue expression of cathepsin D reflect tumor malignancy? The question: does the assay truly mirror cathepsin D mis-function in the tumor?
Nicotra G, Castino R, Follo C, Peracchio C, Valente G, Isidoro C. Nicotra G, et al. Cancer Biomark. 2010;7(1):47-64. doi: 10.3233/CBM-2010-0143. Cancer Biomark. 2010. PMID: 21045264 Review. - Cathepsin D in breast cancer.
Rochefort H. Rochefort H. Breast Cancer Res Treat. 1990 Jul;16(1):3-13. doi: 10.1007/BF01806570. Breast Cancer Res Treat. 1990. PMID: 2207345 Review. - Pepsinogen C expression in tumors of extragastric origin.
Merino AM, Vázquez J, Rodríguez JC, Fernández R, Quintela I, González LO, Sánchez LM, Vizoso F. Merino AM, et al. Int J Biol Markers. 2000 Apr-Jun;15(2):165-70. doi: 10.1177/172460080001500207. Int J Biol Markers. 2000. PMID: 10883891 - Regulation, clinical and biological significance of cathepsin D in breast cancer.
García M, Augereau P, Briozzo P, Capony F, Cavailles V, Freiss G, Maudelonde T, Montcourrier P, Vignon F, Rochefort H. García M, et al. Rev Esp Fisiol. 1990 Mar;46(1):39-41. Rev Esp Fisiol. 1990. PMID: 2204091 Review. - Clinicopathological significance of cathepsin D expression in gastric adenocarcinoma.
Ikeguchi M, Fukuda K, Oka S, Yamaguchi K, Hisamitsu K, Tsujitani S, Sakatani T, Ueda T, Kaibara N. Ikeguchi M, et al. Oncology. 2001;61(1):71-8. doi: 10.1159/000055356. Oncology. 2001. PMID: 11474252
Cited by
- Enhancement of Acetate-Induced Apoptosis of Colorectal Cancer Cells by Cathepsin D Inhibition Depends on Oligomycin A-Sensitive Respiration.
Alves S, Santos-Pereira C, Oliveira CSF, Preto A, Chaves SR, Côrte-Real M. Alves S, et al. Biomolecules. 2024 Apr 12;14(4):473. doi: 10.3390/biom14040473. Biomolecules. 2024. PMID: 38672489 Free PMC article. - Cathepsin D Inhibits Angiogenesis in Pituitary Neuroendocrine Tumors.
Fujiwara R, Ten H, Chen H, Jiang CL, Oyama KI, Onoda K, Matsuno A. Fujiwara R, et al. Acta Histochem Cytochem. 2022 Dec 28;55(6):203-211. doi: 10.1267/ahc.22-00098. Epub 2022 Dec 20. Acta Histochem Cytochem. 2022. PMID: 36688139 Free PMC article. - Pro-cathepsin D as a diagnostic marker in differentiating malignant from benign pleural effusion: a retrospective cohort study.
Choi H, Ko Y, Lee CY. Choi H, et al. BMC Cancer. 2020 Aug 31;20(1):825. doi: 10.1186/s12885-020-07327-w. BMC Cancer. 2020. PMID: 32867726 Free PMC article. - Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer.
Macagno A, Athanasiou A, Wittig A, Huber R, Weber S, Keller T, Rhiel M, Golding B, Schiess R. Macagno A, et al. PLoS One. 2020 May 18;15(5):e0233442. doi: 10.1371/journal.pone.0233442. eCollection 2020. PLoS One. 2020. PMID: 32421745 Free PMC article. - Harnessing the heart's resistance to malignant tumors: cardiac-derived extracellular vesicles decrease fibrosarcoma growth and leukemia-related mortality in rodents.
Grigorian-Shamagian L, Fereydooni S, Liu W, Echavez A, Marbán E. Grigorian-Shamagian L, et al. Oncotarget. 2017 Aug 24;8(59):99624-99636. doi: 10.18632/oncotarget.20454. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29245929 Free PMC article.
References
- Arch Biochem Biophys. 1995 Sep 10;322(1):295-8 - PubMed
- Pathol Res Pract. 1999;195(3):171-5 - PubMed
- Cancer Res. 1986 Oct;46(10):5353-9 - PubMed
- Clin Cancer Res. 1996 Mar;2(3):561-8 - PubMed
- J Pathol. 1996 Jan;178(1):59-64 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources